Long-term results of coronary artery bypass graft surgery after stenting of obstructed artery with bare metal stent in patients with acute coronary syndrome and multivessel disease

封面

如何引用文章

全文:

详细

Non-optimal long-term results of endovascular interventions using bare metal stents and their wide use in Russia in acute coronary syndrome (ACS) make it important to study the influence of the mentioned interventions on the results of coronary artery bypass graft surgery (CABG) performed after stenting of the obstructed artery in patients with ACS and multivessel disease.

Aim. To study the results of CABG performed at our department in early periods of ACS after stenting of an obstructed artery with bare metal stents versus  the results of use of drug coated stents of the 2nd generation, on the basis of the data of NORSTENT study.

Materials and Methods. The work presents the results of a two-year observation of stepwise treatment of 97 patients with ACS and multivessel disease who were performed stenting of an obstructed artery for life-saving indications followed by CABG not later than in 90 days. Patients of the main group had three-vessel disease of coronary arteries with severity of damage 26.0±3.2 points on SYNTAX scale. The time from the moment of stenting to complete revascularization was 64±17 days. Clinico-demographic parameters of the main group were comparable with those of the comparison group (data of NORSTENT study).

Results. During observation time two cases of acute myocardial infarction occurred. Repeat revascularization was required in 14 patients (14.4%). The rate of MACCE was 0.1443. Odd ratio (OR) of the risk of MACCE occurrence was 1.61 (95% CI [1.14;2.78]).

Conclusion. Surgical revascularization of the coronary bed in early periods after stenting of the obstructed artery with bare metal stents in patients with ACS and multivessel disease has 1.6 times (95% CI 1.14;2.78) higher risk for initiation of adverse cardiovascular events, in comparison with endovascular revascularization with use of drug coated stents of the 2nd generation.

作者简介

Aleksandr Bocharov

Kostroma regional clinical hospital named after Korolev E.I., Kostroma, Russia

编辑信件的主要联系方式.
Email: bocharovav@mail.ru
ORCID iD: 0000-0002-6027-2898
SPIN 代码: 6073-1445
Researcher ID: C-6324-2019

MD, PhD, Head of the Department of Roentgenosurgical Methods of Diagnosis and Treatment

俄罗斯联邦, prospect Mira, 114, 156013, Kostroma

参考

  1. Chazova EI, Oschepkova EV. The fight against cardiovascular diseases: problems and solutions at the present stage. Vestnik Roszdravnadzora. 2015; (5):7-10. (In Russ).
  2. Gilard M, Bezon E, Cornily JC, et al. Same-day combined percutaneous coronary intervention and coronary artery surgery. Cardiology. 2007;108(4): 363-7. doi: 10.1159/000099110
  3. Keeley EC, Boura JA, Grines C. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction a quantitative review of 23 randomized trials. Lancet. 2003;361(9351):13-20. doi: 10.1016/S0140-6736(03)12113-7
  4. Fukui T, Tabata M, Tobaru T, et al. Early and long-term outcomes of coronary artery bypass grafting and percutaneous coronary intervention in patients with left main disease: single-center results of multidisciplinary decision making. General Thoracic and Cardiovascular Surgery. 2014;62(5):301-7. doi: 10.1007/s11748-013-0357-7
  5. Ganyukov VI. Evidence base for priority role of primary percutaneous coronary intervention in revascularization of stemi patients. Kompleksnye Problemy Serdečno-Sosudistyh Zabolevanij. 2013; (1):24-34. (In Russ). doi: 10.17802/2306-1278-2013-1-24-34
  6. Hillis AD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery A Report of the American College of Cardiology Foundation/American Heart. Association Task Force on Practice Guidelines. Developed in Collaboration With the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2011;58(24). doi: 10.1016/j.jacc.2011.08.009
  7. Girasis C, Garg S, Räber L, et al. SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacli-TAXel-eluting stent for coronary revascularization (SIRTAX) trial. European Heart Journal. 2011; 32(24):3115-27. doi: 10.1093/eurheartj/ehr369
  8. Mehta RH, Honeycutt E, Shaw LK, et al. Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. American Journal of Cardiology. 2007; 100:1538-42. doi: 10.1016/j.amjcard.2007.06.053
  9. Hayward PA, Buxton BF. Contemporary coronary graft patency: 5-year observation data from a randomized trial of conduits. The Annals of Thoracic Surgery. 2007;84(3):795-9. doi: 10.1016/j.athorac-sur.2007.04.028
  10. Weisz G, Leon MB, Holmes DR Jr, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. Journal of the American College of Cardiology. 2006;47(7): 1350-5. doi: 10.1016/j.jacc.2005.11.077
  11. Stettler C, Wandel S, Alleman S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370(9591):937-48. doi: 10.1016/S0140-6736(07)61444-5
  12. Barbarash LS, Ganyukov VI, Popov VA, et al. Hospital results of treatment of acute coronary syndrome without ST-segment elevation in multivessel coronary artery disease, depending on the method and strategies of revascularization. Kardiologiches-kiy Vestnik. 2013;VIII(XX)(2):17-22. (In Russ).
  13. Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year followup of the SYNTAX trial. European Heart Journal. 2014;35(40):2821-30. doi: 10.1093/eurheartj/ehu213
  14. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-77. doi: 10.1093/eurheartj/ehx393
  15. Stone GW, Grines CL, Rothbaum D, et al. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angiopplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. Journal of the American College of Cardiology. 1997; 29(5):901-7. doi: 10.1016/S0735-1097(97)00041-7
  16. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367(9510): 569-78. doi: 10.1016/S0140-6736(06)68147-6
  17. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. American Journal of Cardiology. 2005;95(1):100-1. doi: 10.1016/j.amjcard.2004.08.069
  18. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine. 2009; 360(10):961-72. doi: 10.1056/NEJMoa0804626
  19. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in pati-ents with diabetes. New England Journal of Medicine. 2012;367(25):2375-84. doi: 10.1056/NEJMoa1211585
  20. Bonaa KH, Mannsverck J, Wiseth R, et al. Drig-Eluting or Bare-Metal Stents for Coronary Artery Disease. New England Journal of Medicine. 2016; 375(13):1242-52. doi: 10.1056/NEJMoa1607991
  21. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of Coronary Angioplasty with Fibrino-lytic Therapy in Acute Myocardial Infarction. New England Journal of Medicine. 2003;349(8):733-42. doi: 10.1056/NEJMoa025142
  22. Tarantini G, Razzolini R, Napodano M, et al. Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific thrombolytic therapy is affected (mainly) by the patients mortality risk: 1 h does not fill all. European Heart Journal. 2010; 31(6):676-83. doi: 10.1093/eurheartj/ehp506

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bocharov A.V., 2020

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##